Key result
An open-access outpatient intravenous diuretic program was utilized by 22.5% of heart failure patients, with no documented adverse reactions and no difference in mortality compared to non-users.
Why the study?
Does an open-access outpatient intravenous diuretic program provide safe and utilized treatment for acute exacerbations in patients with systolic heart failure?
Observational (n=577)
No
Does an open-access outpatient intravenous diuretic program provide safe and utilized treatment for acute exacerbations in patients with systolic heart failure?
An open-access outpatient IV diuretic program is readily utilized by high-risk heart failure patients and appears safe, offering a potential alternative to emergency department visits or hospitalizations for acute exacerbations.
May support efficient outpatient HF exacerbation management in HFDMP; leaves open efficacy and safety pending RCTs.
In order to provide efficient utilization of resources in an outpatient setting for acute exacerbation of heart failure (HF), the authors piloted an open-access outpatient intravenous (IV) diuretic program (IVDP) to evaluate utilization in an HF disease management program (HFDMP), patient characteristics for users of the program, and safety. An outpatient HFDMP at Jackson Memorial Hospital in Miami, Florida, enrolling 577 patients 18 years and older with an ejection fraction ≤40% was implemented. For symptoms or weight gain ≥5 pounds, patients were eligible to use an open-access IVDP during clinic hours. A total of 130 HFDM patients (22.5%) used the IVDP. IVDP users were more likely to be diabetic, with lower body mass indices than non-IVDP users. New York Heart Association class IV patients and previously hospitalized patients were more likely to use the IVDP. There were no documented adverse reactions for patients receiving treatment and no difference in mortality between groups. This open-access outpatient IVDP model for patients with HF was readily utilized by the HFDMP participants and appears safe for use in this population. This unique model may provide alternative access for acute HF treatment. Congest Heart Fail.
No takes yet. Share an insight, caveat, or question.
Hebert et al. (2011) conducted an observational in Systolic Heart Failure (n=577). Open-access outpatient intravenous diuretic program vs. Non-users was evaluated on Utilization of the IV diuretic program. An open-access outpatient intravenous diuretic program was utilized by 22.5% of heart failure patients, with no documented adverse reactions and no difference in mortality compared to non-users.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: